WO2006068596A1 - Solid dosage form comprising proton pump inhibitor and suspension made thereof - Google Patents

Solid dosage form comprising proton pump inhibitor and suspension made thereof Download PDF

Info

Publication number
WO2006068596A1
WO2006068596A1 PCT/SE2005/001972 SE2005001972W WO2006068596A1 WO 2006068596 A1 WO2006068596 A1 WO 2006068596A1 SE 2005001972 W SE2005001972 W SE 2005001972W WO 2006068596 A1 WO2006068596 A1 WO 2006068596A1
Authority
WO
WIPO (PCT)
Prior art keywords
suspension
dosage form
form according
granulate
modifying granulate
Prior art date
Application number
PCT/SE2005/001972
Other languages
English (en)
French (fr)
Inventor
Eva Persson
Eva Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36602062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2006068596(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL05820824T priority Critical patent/PL1830816T3/pl
Priority to NZ555833A priority patent/NZ555833A/en
Priority to BRPI0519186-6A priority patent/BRPI0519186A2/pt
Priority to AU2005319732A priority patent/AU2005319732B2/en
Priority to CA2592030A priority patent/CA2592030C/en
Priority to KR1020077014098A priority patent/KR101321641B1/ko
Priority to CN2005800441944A priority patent/CN101087590B/zh
Priority to DK05820824.0T priority patent/DK1830816T3/da
Priority to ES05820824T priority patent/ES2389844T3/es
Priority to US11/722,387 priority patent/US20080020053A1/en
Priority to JP2007548145A priority patent/JP5171259B2/ja
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SI200531586T priority patent/SI1830816T1/sl
Priority to MX2007007423A priority patent/MX2007007423A/es
Priority to UAA200706656A priority patent/UA87341C2/ru
Priority to EP05820824A priority patent/EP1830816B1/en
Priority to MEP-2012-106A priority patent/ME01458B/me
Priority to RS20120403A priority patent/RS52472B/en
Publication of WO2006068596A1 publication Critical patent/WO2006068596A1/en
Priority to IL183658A priority patent/IL183658A/en
Priority to ZA2007/05113A priority patent/ZA200705113B/en
Priority to NO20073731A priority patent/NO20073731L/no
Priority to HK08102573.3A priority patent/HK1111609A1/xx
Priority to HK08105386.3A priority patent/HK1115308A1/xx
Priority to HRP20120719TT priority patent/HRP20120719T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PCT/SE2005/001972 2004-12-22 2005-12-20 Solid dosage form comprising proton pump inhibitor and suspension made thereof WO2006068596A1 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
RS20120403A RS52472B (en) 2004-12-22 2005-12-20 SOLID DOSAGE FORM CONTAINING PROTON PUMP INHIBITOR AND ITS SUSPENSION
MX2007007423A MX2007007423A (es) 2004-12-22 2005-12-20 Forma de dosis solida que comprende inhibidor de la bomba de protones y suspension elaborada del mismo.
SI200531586T SI1830816T1 (sl) 2004-12-22 2005-12-20 Dozirni pripravek v trdni obliki, ki vsebuje inhibitor protonske ÄŤrpalke in iz njega narejena suspenzija
AU2005319732A AU2005319732B2 (en) 2004-12-22 2005-12-20 Solid dosage form comprising proton pump inhibitor and suspension made thereof
NZ555833A NZ555833A (en) 2004-12-22 2005-12-20 Solid dosage form comprising proton pump inhibitor and suspension made thereof
KR1020077014098A KR101321641B1 (ko) 2004-12-22 2005-12-20 양성자 펌프 억제제를 포함하는 고체 투여 형태 및 그의제조된 현탁액
CN2005800441944A CN101087590B (zh) 2004-12-22 2005-12-20 包含质子泵抑制剂的固体剂型和由其制成的混悬液
UAA200706656A UA87341C2 (ru) 2004-12-22 2005-12-20 Твердая лекарственная форма, содержащая ингибитор протонного насоса, и полученная из нее суспензия
ES05820824T ES2389844T3 (es) 2004-12-22 2005-12-20 Forma de dosificación sólida que comprende inhibidor de la bomba de protones, y suspensión obtenida de ella
US11/722,387 US20080020053A1 (en) 2004-12-22 2005-12-20 Solid Dosage Form Comprising Proton Pump Inhibitor and Suspension Made Thereof
JP2007548145A JP5171259B2 (ja) 2004-12-22 2005-12-20 プロトンポンプインヒビターを包含する固形剤形およびそれから調製された懸濁剤
PL05820824T PL1830816T3 (pl) 2004-12-22 2005-12-20 Stała postać dawkowana zawierająca inhibitor pompy protonowej i wytworzona z niej zawiesina
BRPI0519186-6A BRPI0519186A2 (pt) 2004-12-22 2005-12-20 forma de dosagem farmacÊutica oral, sachÊ, formulaÇço lÍquida pronta para o uso, processos para a preparaÇço e para a fabricaÇço do granulado modificador de suspensço, mÉtodo de tratamento de doenÇas relacionadas com Ácido gÁstrico no homem, e, uso de uma forma de dosagem farmacÊutica
CA2592030A CA2592030C (en) 2004-12-22 2005-12-20 Solid dosage form comprising proton pump inhibitor and suspension made thereof
DK05820824.0T DK1830816T3 (da) 2004-12-22 2005-12-20 Fast doseringsform, der omfatter protonpumpeinhibitor, og suspension fremstillet deraf
EP05820824A EP1830816B1 (en) 2004-12-22 2005-12-20 Solid dosage form comprising proton pump inhibitor and suspension made thereof
MEP-2012-106A ME01458B (me) 2004-12-22 2005-12-20 Kruta dozna forma koja sadrži inhibitor protonske pumpe i njena suspenzija
IL183658A IL183658A (en) 2004-12-22 2007-06-04 A solid capsule consisting of a proton channel inhibitor and a compound made of it
ZA2007/05113A ZA200705113B (en) 2004-12-22 2007-06-18 Solid dosage form comprising proton pump inhibitor and suspension made thereof
NO20073731A NO20073731L (no) 2004-12-22 2007-07-18 Fast doseringsform omfattende protonpumpeinhibitor, og suspensjon fremstilt derav
HK08102573.3A HK1111609A1 (en) 2004-12-22 2008-03-05 Solid dosage form comprising proton pump inhibitor and suspension made thereof
HK08105386.3A HK1115308A1 (en) 2004-12-22 2008-05-15 Solid dosage form comprising proton pump inhibitor and suspension made thereof
HRP20120719TT HRP20120719T1 (hr) 2004-12-22 2012-09-10 Kruti oblik doziranja koji sadrži inhibitor protonske pumpe i od njega dobivena suspenzija

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63843504P 2004-12-22 2004-12-22
US60/638,435 2004-12-22

Publications (1)

Publication Number Publication Date
WO2006068596A1 true WO2006068596A1 (en) 2006-06-29

Family

ID=36602062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2005/001972 WO2006068596A1 (en) 2004-12-22 2005-12-20 Solid dosage form comprising proton pump inhibitor and suspension made thereof

Country Status (30)

Country Link
US (5) US20060134210A1 (ru)
EP (1) EP1830816B1 (ru)
JP (1) JP5171259B2 (ru)
KR (1) KR101321641B1 (ru)
CN (1) CN101087590B (ru)
AR (1) AR052173A1 (ru)
AU (1) AU2005319732B2 (ru)
BR (1) BRPI0519186A2 (ru)
CA (1) CA2592030C (ru)
CY (1) CY1113207T1 (ru)
DK (1) DK1830816T3 (ru)
ES (1) ES2389844T3 (ru)
HK (2) HK1111609A1 (ru)
HR (1) HRP20120719T1 (ru)
IL (1) IL183658A (ru)
ME (1) ME01458B (ru)
MX (1) MX2007007423A (ru)
MY (1) MY149156A (ru)
NO (1) NO20073731L (ru)
NZ (1) NZ555833A (ru)
PL (1) PL1830816T3 (ru)
PT (1) PT1830816E (ru)
RS (1) RS52472B (ru)
RU (1) RU2397756C2 (ru)
SA (1) SA05260421B1 (ru)
SI (1) SI1830816T1 (ru)
TW (1) TWI478735B (ru)
UA (1) UA87341C2 (ru)
WO (1) WO2006068596A1 (ru)
ZA (1) ZA200705113B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
US8241664B2 (en) 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
WO2009105568A1 (en) 2008-02-20 2009-08-27 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
EP2257220B1 (en) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Multi-function, foot-activated controller for imaging system
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
JP2012072061A (ja) * 2009-01-29 2012-04-12 Eisai R & D Management Co Ltd 新規組成物
US20130052278A1 (en) * 2010-03-11 2013-02-28 Rich Vitamins Llc Quick dissolve nutritional powder
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
GB201306720D0 (en) 2013-04-12 2013-05-29 Special Products Ltd Formulation
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
EP3117824A1 (en) 2015-07-17 2017-01-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
HRP20230250T1 (hr) 2015-07-17 2023-04-14 BE Pharbel Manufacturing Višeslojni farmaceutski aktivne mikročestice, koje otpuštaju spoj u tekućem obliku doziranja
CN107468652A (zh) * 2016-06-07 2017-12-15 北京新领先医药科技发展有限公司 一种固体干混悬温敏凝胶剂及其制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3523288A4 (en) * 2016-10-06 2020-05-27 Jubilant Generics Limited PHARMACEUTICAL FORM OF A PHARMACEUTICAL SUSPENSION FROM BENZIMIDAZOLE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
CN108201527A (zh) * 2016-12-16 2018-06-26 广州共禾医药科技有限公司 一种包含质子泵抑制剂的缓释干混悬剂及其制备方法
JP6964369B1 (ja) * 2021-02-10 2021-11-10 共和薬品工業株式会社 速崩壊性ゲル皮膜

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731002A (en) * 1993-04-30 1998-03-24 Astra Aktiebolag Veterinary composition
US6261602B1 (en) * 1996-10-23 2001-07-17 Eurand International S.P.A. Pharmaceutical composition for rapid suspension in aqueous media
EP1232746A1 (en) * 2001-02-14 2002-08-21 ForTe Beheer B.V. Pharmaceutical composition comprising xanthan gum
WO2004004718A1 (en) * 2002-07-03 2004-01-15 Abbott Laboratories Liquid dosage forms of acid labile drugs
US20040170684A1 (en) * 1999-09-30 2004-09-02 Penwest Pharmaceuticals Co. Sustained release matrix systems for highly soluble drugs

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
US5288500A (en) * 1987-03-13 1994-02-22 Benzon Pharma A/S Oral composition containing particles comprising an active substance
DK130287D0 (da) * 1987-03-13 1987-03-13 Benzon As Alfred Oralt praeparat
IT1246350B (it) * 1990-07-11 1994-11-17 Eurand Int Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili
JP3802555B2 (ja) * 1991-12-17 2006-07-26 フイズ テクノロジーズ リミテッド 潰瘍予防及び治療組成物並びに方法
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
ES2217410T3 (es) * 1996-04-16 2004-11-01 Novartis Consumer Health S.A. Forma de dosificacion oral de rapida desintegracion.
US6362009B1 (en) * 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
PL195266B1 (pl) * 1997-12-08 2007-08-31 Altana Pharma Ag Jednostka związku aktywnego nietrwałego w środowisku kwaśnym, sposób jej otrzymywania, czopki zawierające aktywny związek nietrwały w środowisku kwaśnym oraz sposób ich otrzymywania
US6013821A (en) * 1998-06-25 2000-01-11 Abbott Laboratories Removal of silylated compounds from solvent and gas waste streams
US6194395B1 (en) * 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
CA2376202C (en) * 1999-06-07 2008-11-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel preparation and administration form comprising an acid-labile active compound
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US6605302B2 (en) * 2001-07-17 2003-08-12 Osmotica Corp. Drug delivery device containing oseltamivir and an H1 antagonist
US20040081700A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Dose titratable liquid dosage forms of acid labile drugs
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040081671A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
US20040006109A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
WO2005011637A1 (ja) * 2003-08-04 2005-02-10 Eisai Co., Ltd. 用時分散型製剤
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
TW200740724A (en) * 2005-07-15 2007-11-01 Wyeth Corp Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731002A (en) * 1993-04-30 1998-03-24 Astra Aktiebolag Veterinary composition
US6261602B1 (en) * 1996-10-23 2001-07-17 Eurand International S.P.A. Pharmaceutical composition for rapid suspension in aqueous media
US20040170684A1 (en) * 1999-09-30 2004-09-02 Penwest Pharmaceuticals Co. Sustained release matrix systems for highly soluble drugs
EP1232746A1 (en) * 2001-02-14 2002-08-21 ForTe Beheer B.V. Pharmaceutical composition comprising xanthan gum
WO2004004718A1 (en) * 2002-07-03 2004-01-15 Abbott Laboratories Liquid dosage forms of acid labile drugs

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Product specification for Lanzo, 30 mg granules for oral suspension: ASPno: 1998-0084, NPL-id:19991007000057, Swedish Marketing: 14463, First approval date: 1999-10-07, Marketing Authorisation Holder: Wyeth Lederle Nordiska AB; product specification issued by the Swedisch Medical Products Agency ...", ANNOUNCEMENT LAEKEMEDELSVERKET, XX, XX, 7 October 1999 (1999-10-07), XX, pages 1 - 2, XP002997521 *
"Product summary Produktresume for the above mentioned medical product Lanzo, in the form of granules for oral suspension; date for first approval for sale: 1999-10-07, date for review of the Product Summary: 2004-03-23; the Swedish Medical Products Agency (Lakemedelsverket);article in Swedish, 5 ...", ANNOUNCEMENT LAEKEMEDELSVERKET, XX, XX, 23 March 2004 (2004-03-23), XX, pages 1 - 5, XP002997522 *
See also references of EP1830816A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors

Also Published As

Publication number Publication date
BRPI0519186A2 (pt) 2008-12-30
SI1830816T1 (sl) 2012-10-30
EP1830816A4 (en) 2011-06-15
US20080020053A1 (en) 2008-01-24
MY149156A (en) 2013-07-15
UA87341C2 (ru) 2009-07-10
EP1830816A1 (en) 2007-09-12
ES2389844T3 (es) 2012-11-02
CY1113207T1 (el) 2016-04-13
PL1830816T3 (pl) 2012-11-30
IL183658A (en) 2014-04-30
SA05260421B1 (ar) 2010-03-08
CA2592030C (en) 2014-01-28
JP2008525433A (ja) 2008-07-17
HRP20120719T1 (hr) 2012-10-31
CA2592030A1 (en) 2006-06-29
TWI478735B (zh) 2015-04-01
NO20073731L (no) 2007-09-24
US20150079186A1 (en) 2015-03-19
ZA200705113B (en) 2009-12-30
PT1830816E (pt) 2012-09-11
RS52472B (en) 2013-02-28
HK1115308A1 (en) 2008-11-28
MX2007007423A (es) 2007-07-17
US20130273168A1 (en) 2013-10-17
HK1111609A1 (en) 2008-08-15
AU2005319732A1 (en) 2006-06-29
KR101321641B1 (ko) 2013-10-22
CN101087590B (zh) 2012-06-13
US20060134210A1 (en) 2006-06-22
CN101087590A (zh) 2007-12-12
KR20070094610A (ko) 2007-09-20
EP1830816B1 (en) 2012-08-01
TW200635618A (en) 2006-10-16
IL183658A0 (en) 2007-09-20
AR052173A1 (es) 2007-03-07
NZ555833A (en) 2009-10-30
DK1830816T3 (da) 2012-10-01
JP5171259B2 (ja) 2013-03-27
AU2005319732B2 (en) 2008-12-11
RU2397756C2 (ru) 2010-08-27
US20170165248A1 (en) 2017-06-15
ME01458B (me) 2014-04-20
RU2007127781A (ru) 2009-01-27

Similar Documents

Publication Publication Date Title
AU2005319732B2 (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
JP4649001B2 (ja) オメプラゾール製剤
US6132770A (en) Multiple unit effervescent dosage forms comprising proton pump inhibitor
AU774278B2 (en) Pharmaceutical formulation comprising omeprazole
JP4885347B2 (ja) 酸に不安定ベンズイミダゾールを含有する修飾された放出特性の経口用固形製剤
US20080003281A1 (en) Modified Release Tablet Formulations for Proton Pump Inhibitors
PT2258351E (pt) Grânulos contendo lansoprazole em grande quantidade
EP1646404B1 (en) Solid composition comprising a proton pump inhibitor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 183658

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2005319732

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 555833

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 4584/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 07061036

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/007423

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2592030

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11722387

Country of ref document: US

Ref document number: 2007548145

Country of ref document: JP

Ref document number: 200580044194.4

Country of ref document: CN

Ref document number: 1020077014098

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12007501373

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005319732

Country of ref document: AU

Date of ref document: 20051220

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2005820824

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005319732

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007127781

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005820824

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11722387

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0519186

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2012/0403

Country of ref document: RS